ADC-012

ADC-012 is a preclinical antibody-drug conjugate (ADC) being developed by iProgen Biotech in collaboration with Celltrion for the treatment of oncology. The drug utilizes iProgen's proprietary site-specific conjugation technology, which aims to improve the therapeutic index by ensuring a homogeneous drug-to-antibody ratio (DAR). ADC-012 features a small-molecule payload conjugated to a monoclonal antibody backbone, potentially leveraging Celltrion's expertise in biosimilar development. As of 2024, the specific tumor-associated antigen target for ADC-012 remains undisclosed in primary company pipeline documentation.